6 results on '"Brunetti, Maurizio"'
Search Results
2. Analysis of differential therapeutic strategies for primary breast lymphoma: two case reports.
- Author
-
Stasi R, Evangelista ML, Brunetti M, Bussa S, Maritati R, Turrini L, Taccogna S, Crescenzi A, and Angelini F
- Subjects
- Adult, Aged, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Murine-Derived, Antigens, CD20, Antimetabolites, Antineoplastic administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bleomycin therapeutic use, Breast chemistry, Breast pathology, Breast physiopathology, Breast Neoplasms blood, Breast Neoplasms pathology, Breast Neoplasms physiopathology, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Humans, Immunohistochemistry, Injections, Spinal, L-Lactate Dehydrogenase blood, Leucovorin therapeutic use, Leukocyte Common Antigens, Lymphoma, Large B-Cell, Diffuse blood, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse physiopathology, Mastectomy, Segmental, Methotrexate administration & dosage, Methotrexate therapeutic use, Neoplasm Staging, Prednisone therapeutic use, Rituximab, Vincristine therapeutic use, Breast Neoplasms therapy, Lymphoma, Large B-Cell, Diffuse therapy
- Abstract
Primary breast lymphoma (PBL) is a rare form of extranodal non-Hodgkin's lymphoma (NHL), whose own specific biological characteristics still need to be fully defined. No significant prognostic factor has been found and the optimal therapeutic strategy is uncertain. However, an intensified systemic therapy has been advocated to prevent relapse, even in patients who show a complete response to local treatment. We report two cases of primary diffuse large B-cell breast lymphoma, review the literature about this topic, and discuss treatment options. We conclude that differential therapeutic strategies based on the risk of relapse associated with the International Prognostic Index (IPI) are a reasonable way to approach PBL, and can avoid undue toxicity deriving from treatment.
- Published
- 2009
- Full Text
- View/download PDF
3. Percutaneous laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: Results of a phase II study.
- Author
-
Pacella CM, Valle D, Bizzarri G, Pacella S, Brunetti M, Maritati R, Osborn J, and Stasi R
- Subjects
- Adult, Aged, Aged, 80 and over, Catheter Ablation instrumentation, Female, Humans, Hyperthermia, Induced instrumentation, Lasers adverse effects, Male, Middle Aged, Neoadjuvant Therapy, Treatment Outcome, Cardiac Catheterization, Catheter Ablation methods, Colorectal Neoplasms pathology, Hyperthermia, Induced methods, Laser Therapy, Liver Neoplasms secondary, Liver Neoplasms therapy
- Abstract
We prospectively evaluated the safety, local tumor control, and impact on survival parameters of percutaneous laser ablation (PLA) in patients with colorectal liver metastases not amenable to surgical resection. The study included 44 individuals with 75 unresectable liver metastases and no known extrahepatic disease. The median number of metastases treated for each patient was one, with a range of 1-4. Metastases had a median diameter of 3.4 cm (range 0.5-9 cm), and a median volume of 16.8 cm(3) (range 0.4-176.4 cm(3)). All patients also received systemic chemotherapy with modalities that differed according to the type of response to PLA. After treatment, 61% (46/75) of the tumors were ablated completely. The likelihood of achieving a complete ablation was significantly higher when metastases had a diameter <3.0 cm (p = 0.004). Overall survival was 30.0+/-12.7 months in patients with a complete ablation, and 20.2+/-10.2 months in those with a partial ablation (p = 0.002). There were no major complications during or after PLA, the most frequent side effect being abdominal pain that required analgesics. These findings indicate that PLA can be safely used as an adjunct to chemotherapy in unresectable colorectal liver metastases, and may have a positive impact on survival.
- Published
- 2006
- Full Text
- View/download PDF
4. Unsuspected testicular metastases from Merkel cell carcinoma: a case report with therapeutic implications.
- Author
-
Rufini V, Perotti G, Brunetti M, Crescenzi A, Fadda G, and Troncone L
- Subjects
- Adult, Carcinoma, Merkel Cell diagnosis, Fatal Outcome, Humans, Male, Skin Neoplasms diagnosis, Testicular Neoplasms diagnosis, Carcinoma, Merkel Cell secondary, Skin Neoplasms pathology, Testicular Neoplasms secondary
- Published
- 2004
- Full Text
- View/download PDF
5. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.
- Author
-
Stasi R, Brunetti M, Stipa E, and Amadori S
- Subjects
- Adult, Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Disease Progression, Factor VIII antagonists & inhibitors, Female, Humans, Lymphocyte Depletion, Male, Middle Aged, Monitoring, Immunologic, Rituximab, Time Factors, Antibodies, Monoclonal therapeutic use, von Willebrand Diseases drug therapy, von Willebrand Diseases immunology
- Abstract
The activity and safety profile of selective B-cell depletion with rituximab, an anti-CD20 monoclonal antibody, were evaluated in 10 patients with acquired hemophilia. Rituximab was given intravenously at the dose of 375 mg/m(2) once weekly for 4 consecutive weeks. Infusion-related side effects were observed in 3 patients but were of mild intensity and did not require discontinuation of treatment. Eight patients with Factor VIII (FVIII) inhibitor titers between 4 and 96 Bethesda units per milliliter (BU/mL) achieved a complete remission, which was defined as a return to normal FVIII activity and undetectable FVIII inhibitor titers. Two more patients with inhibitor levels greater than 100 BU/mL experienced only a partial transient decrease of the inhibitor after rituximab alone, but they achieved a complete response after being challenged with a combination of rituximab plus pulse intravenous cyclophosphamide. With a median follow-up of 28.5 months (range, 12-41 months), 3 patients have thus far relapsed. Retreatment with the monoclonal antibody at the same dose and schedule resulted in a new sustained response in all these patients. In conclusion, rituximab appears an effective and well-tolerated treatment for patients with acquired hemophilia and low inhibitor titers. A reinforcement of therapy with other agents seems to be required to achieve a full and durable response in those patients with high inhibitor levels.
- Published
- 2004
- Full Text
- View/download PDF
6. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes.
- Author
-
Stasi R, Brunetti M, Terzoli E, and Amadori S
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols toxicity, Drug Administration Schedule, Drug Synergism, Erythropoietin toxicity, Female, Follow-Up Studies, Hematopoiesis drug effects, Hemoglobins metabolism, Humans, Leukocyte Count, Male, Middle Aged, Myelodysplastic Syndromes blood, Neutrophils cytology, Neutrophils drug effects, Platelet Count, Recombinant Proteins, Treatment Outcome, Tretinoin toxicity, Erythropoietin administration & dosage, Myelodysplastic Syndromes drug therapy, Tretinoin administration & dosage
- Abstract
In vitro studies suggest that all-trans retinoic acid (ATRA) synergizes with erythropoietin (EPO) for the stimulation of hematopoiesis in patients with myelodysplastic syndrome (MDS). A clinical trial was performed to evaluate whether a combination of these agents was effective in relieving the cytopenias associated with MDS. Twenty-seven patients with low- or intermediate-risk MDS were enrolled in a 12-week study. ATRA was administered orally at the dose of 80 mg/m(2) per day in 2 divided doses for 7 consecutive days every other week. Recombinant human EPO was given subcutaneously 3 times a week. The EPO dose was initiated at 150 U/kg and was increased to 300 U/kg if after 6 weeks there was no or there was suboptimal erythroid response. Patients who responded to therapy were continued on ATRA and EPO at the same doses for 6 additional months (extension phase). Further treatment was given to patients with a continued response. Clinically significant erythroid responses with increases of hemoglobin levels of at least 1 g/dL or reduction of transfusion needs were seen in 13 (48%) patients, with 4 showing improved responses after dose escalation of EPO. Ten (37%) patients displayed continued responses during 6 months of extended treatment, and 7 (26%) are still responsive after a follow-up period of 13 months. Neutrophil responses were observed in 5 of 12 patients with neutropenia, and platelet responses were observed in 6 of 9 patients with thrombocytopenia. Three patients displayed trilineage responses that were sustained during continuation therapy. Side effects were observed in all patients but were of mild entity and did not require discontinuation of therapy. It is concluded that the combination ATRA + EPO is an effective and well-tolerated treatment for patients with low- and intermediate-risk MDS. The optimal ATRA and EPO schedule and the role of maintenance treatment remain to be determined and warrant further investigation.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.